MiR-181a is elevated in MASLD and directly acts on PPARα, regulating lipid metabolism, which suggests that inhibiting miR-181a could be a therapeutic strategy [51]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.